Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Erritzoe

Showing results (81-90 of 143) with videos related to

Pageof 15
Sort By:
Scientific Reports|January 29, 2025
From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS)Richard J Zeifman, Meg J Spriggs, Hannes Kettner, et al.
Neuroscience and Biobehavioral Reviews|April 4, 2025
Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical modelsClaudio Agnorelli, Meg Spriggs, Kate Godfrey, et al.
Frontiers in Psychiatry|August 22, 2025
Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreatGrace Blest-Hopley, Giuseppe Pasculli, Simon G D Ruffell, et al.
Neuroimage|February 24, 2009
High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter bindingVibe G Frokjaer, Maj Vinberg, David Erritzoe, et al.
Frontiers in Psychology|June 23, 2025
Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studiesWilliam Roseby, Hannes Kettner, Leor Roseman, et al.
Journal of Psychopharmacology (Oxford, England)|August 4, 2022
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sampleVictoria Amalie Nygart, Lis Marie Pommerencke, Eline Haijen, et al.
Psychological Medicine|July 19, 2023
Personality Change in a Trial of Psilocybin Therapy vs Escitalopram Treatment for Depression - CORRIGENDUMBrandon Weiss, Induni Ginige, Lu Shannon, et al.
Journal of Psychopharmacology (Oxford, England)|September 8, 2016
Serotonergic neurotransmission in emotional processing: New evidence from long-term recreational poly-drug ecstasy useHelle Ruff Laursen, Susanne Henningsson, Julian Macoveanu, et al.
Scientific Reports|July 17, 2024
Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapySara de la Salle, Hannes Kettner, Julien Thibault Lévesque, et al.
Eclinicalmedicine|January 7, 2025
Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trialDavid Erritzoe, Tommaso Barba, Kyle T Greenway, et al.
Pageof 15

Showing results (81-90 of 143) with videos related to

Sort By:
Pageof 15
Scientific Reports|January 29, 2025
From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS)Richard J Zeifman, Meg J Spriggs, Hannes Kettner, et al.
Neuroscience and Biobehavioral Reviews|April 4, 2025
Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical modelsClaudio Agnorelli, Meg Spriggs, Kate Godfrey, et al.
Frontiers in Psychiatry|August 22, 2025
Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreatGrace Blest-Hopley, Giuseppe Pasculli, Simon G D Ruffell, et al.
Neuroimage|February 24, 2009
High familial risk for mood disorder is associated with low dorsolateral prefrontal cortex serotonin transporter bindingVibe G Frokjaer, Maj Vinberg, David Erritzoe, et al.
Frontiers in Psychology|June 23, 2025
Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studiesWilliam Roseby, Hannes Kettner, Leor Roseman, et al.
Journal of Psychopharmacology (Oxford, England)|August 4, 2022
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sampleVictoria Amalie Nygart, Lis Marie Pommerencke, Eline Haijen, et al.
Psychological Medicine|July 19, 2023
Personality Change in a Trial of Psilocybin Therapy vs Escitalopram Treatment for Depression - CORRIGENDUMBrandon Weiss, Induni Ginige, Lu Shannon, et al.
Journal of Psychopharmacology (Oxford, England)|September 8, 2016
Serotonergic neurotransmission in emotional processing: New evidence from long-term recreational poly-drug ecstasy useHelle Ruff Laursen, Susanne Henningsson, Julian Macoveanu, et al.
Scientific Reports|July 17, 2024
Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapySara de la Salle, Hannes Kettner, Julien Thibault Lévesque, et al.
Eclinicalmedicine|January 7, 2025
Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trialDavid Erritzoe, Tommaso Barba, Kyle T Greenway, et al.
Pageof 15